Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Nivolumab in Metastatic Renal Cell Cancer Patients - Japanese Real-World Data Through Clinical Chart Review

NCT03568435 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03568435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03568435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Nivolumab in Metastatic Renal Cell Cancer Patients - Japanese Real-World Data Through Clinical Chart Review
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
February 14, 2018
Completion date
December 21, 2020
Enrollment
212 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, renal cancer